date/time interval
- October 1, 2022 - September 30, 2024
Identifying synthetically lethal compounds for therapy of homologous recombination deficient (HRD) breast cancers
Grant
Overview
awarded by
administered by
sponsor award ID
- MSKCC 226481-01
Affiliation
contributor
- Holloman, William K. Principal Investigator (Subaward) 2022 - 2023